CD19 CAR mRNA (Human) 

CD19 CAR mRNA (Human) expresses Human CD19 CAR protein. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia^[1][2][3].

指南 (以下是我们推荐的协议。该协议仅供参考，应根据您的具体需求进行修改)。
1. 原代 T 细胞培养
1.1 使用 LympPrep 梯度离心法从新鲜静脉原代血中分离原代人 T 细胞。
1.2 纯化至纯度 95%。
1.3 使用前保存于液氮中。
1.4 解冻细胞，并在完全培养基中培养 24 小时。
1.5 用 Human T-Activator CD3/CD28 Dynabeads (细胞与磁珠比例为 1:1) 激活，孵育 48 小时。
1.6 轻轻用移液器上下取出 Human T-Activator 磁珠，然后将其转移到磁力架上静置 1-2 分钟，将含有细胞的上清液转移到新的试管中。
1.7 取出磁珠后 24 小时内对细胞进行电穿孔。
2. mRNA 转染
2.1 除非另有说明，否则每个系统添加 50 ng/μL (triDrop 每次反应 50 ng，Neon 每次反应 500 ng，Lonza 每次反应 1000 ng)。
2.2 将 CD19 CAR mRNA 分装于 -80 ℃ 保存
3. 电穿孔
3.1 使用 triDrop、Neon 或 Lonza 电穿孔方案进行电穿孔。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

液体

Colorless to light yellow

Shipping with dry ice.

-80°C

• [1]. K. Xiao, et al., mRNA-based chimeric antigen receptor T cell therapy: Basic principles, recent advances and future directions Interdiscip. Med. 2024, 2, e20230036.

  [2]. Wang, K., et al., (2012). CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental hematology & oncology, 1(1), 36.  [Content Brief]

  [3]. Wu, J., et al., (2024). Chimeric antigen receptor therapy meets mRNA technology. Trends in biotechnology, 42(2), 228–240.  [Content Brief]